BioCardia, Inc. (BCDA)

NASDAQ: BCDA · IEX Real-Time Price · USD
+0.02 (0.98%)
At close: Mar 24, 2023, 4:00 PM
+0.02 (0.97%)
After-hours: Mar 24, 2023, 4:00 PM EDT

Company Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.

Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.

The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure.

In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths.

The company is based in Sunnyvale, California.

BioCardia, Inc.
BioCardia logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 28
CEO Peter Altman

Contact Details

125 Shoreway Road, Suite B
San Carlos, California 94070
United States
Phone 650-226-0123

Stock Details

Ticker Symbol BCDA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000925741
CUSIP Number 09060U507
ISIN Number US09060U5074
Employer ID 23-2753988
SIC Code 2836

Key Executives

Name Position
Dr. Peter A. Altman Ph.D. Chief Executive Officer, President and Director
David McClung Chief Financial Officer
Edward M. Gillis Senior Vice President of Devices
Dr. Ian McNiece Ph.D. Chief Scientific Officer
Dr. Sujith Shetty Chief Medical Officer and Vice President of Clinical and Regulatory

Latest SEC Filings

Date Type Title
Mar 6, 2023 8-K Current Report
Feb 13, 2023 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 1, 2023 8-K Current Report
Jan 9, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Jan 9, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Dec 28, 2022 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Dec 22, 2022 EFFECT Notice of Effectiveness
Dec 22, 2022 8-K Current Report
Dec 19, 2022 S-3 Registration statement under Securities Act of 1933
Dec 15, 2022 8-K Current Report